The independent source for health policy research, polling, and news.
561 - 580 of 698 Results
Some of the nation鈥檚 most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
In this episode of 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the possible impact of the tax bill on the Medicare program, confirmation hearings for a new secretary of Health and Human Services and the future of the Children鈥檚 Health Insurance Program. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
The price for Pfizer鈥檚 Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
In this episode of 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Alice Ollstein of Talking Points Memo and Sarah Jane Tribble of Kaiser Health News discuss some of the under-covered health stories of the past several weeks, including drug price issues, the opioid epidemic and women鈥檚 reproductive health.
In an effort to reduce drug costs and increase efficiency, Massachusetts is seeking federal approval to implement a new approach to how the state鈥檚 Medicaid program covers prescription medications.
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor鈥檚 office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
UnitedHealth, a health industry goliath, has its hand in doctors鈥 offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are 鈥榳annabes.鈥
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers 鈥 middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
"If it gets signed by this governor, it's going to send shock waves throughout the country,鈥 one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
漏 2026 KFF